What does PHARMA PLUS do?

PHARMA PLUS is a pharmacy in Boussu. Private Limited, started on 21 December 1987, 1 establishment.

What is the address of PHARMA PLUS?

The registered office of PHARMA PLUS is located at Rue Alfred Dendal(B) 192, 7300 Boussu.

Is PHARMA PLUS still active?

Yes. According to the CBE (29 October 2026) PHARMA PLUS is active, legal situation “Normale toestand”, started on 21 December 1987.

Is PHARMA PLUS registered on Peppol?

Yes, PHARMA PLUS is registered on the Peppol network with ID 0208:0432850028.

What is the enterprise number of PHARMA PLUS?

The enterprise number of PHARMA PLUS is BE0432850028.

When was PHARMA PLUS founded?

PHARMA PLUS was founded on 21 December 1987.

Who are the directors of PHARMA PLUS?

According to the 2025 annual accounts, the directors of PHARMA PLUS are: Sodiap SRL, Alexo SRL.

Is PHARMA PLUS a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 21 December 1987; 5 annual accounts filed, latest fiscal year 2025; 2 directors known from the annual account.

How much profit did PHARMA PLUS make in 2025?

PHARMA PLUS posted a profit after taxes of € 15,884 in financial year 2025.

What is the revenue of PHARMA PLUS?

As a small company, PHARMA PLUS is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € 248,353.

How much does an employee at PHARMA PLUS earn?

The average wage cost per full-time employee at PHARMA PLUS was € 52,800 in 2025: staff costs of € 216,406 for 4.1 FTE, according to the annual account at the National Bank. That is the employer's cost, not net pay.

How many employees does PHARMA PLUS have?

According to the 2025 annual accounts, PHARMA PLUS has 4.1 full-time equivalents (FTE).

PHARMA PLUS (Private Limited) - Boussu - BE0432850028

Dossier PHARMA PLUS, printed on 29 October 2026 from databakkes.be/en/0432850028/pharma-plus. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Warning lights

Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.

Shrinking team NBB

FTE fell two years in a row, from 5.9 to 4.1.

Financials

Financial year 2025

PHARMA PLUS from Boussu, company number BE0432850028, closed financial year 2025 with a result of € 15,884 after tax. For that financial year PHARMA PLUS recorded a gross margin of € 248,353 and equity of € 876,038. Compared with financial year 2024, the result moved from € 78,352 to € 15,884. The company is profitable. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on May 12, 2026.

What it is worth Growing

€ 876,038

▲ 2% vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Profit Healthy

€ 15,884

▼ 80% vs 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 5,375

▼ 2% vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Growing

Stays in the company

No dividend for 2025. Retained profit grew to € 814,038.

People and assets in 2025

Full-time equivalents

4.1

▼ 0.1 vs 2024

Average over the fiscal year, from the social balance sheet.

Wage cost

€ 216,406

▲ 4% vs 2024

€ 52,800 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.

Vehicles and equipment

€ 15,725

▲ € 14,220 vs 2024

Book value of vehicles, furniture and equipment.

Debts at end 2025

Bank debt

None

No bank loans on the last day of the fiscal year.

Owed to suppliers

€ 104,694

▼ 25% vs 2024

Supplier invoices still open on the last day of the fiscal year.

Taxes and wages

€ 47,609

▼ 3% vs 2024

Taxes, VAT and social contributions still to pay.

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Gross margin	€ 483,482 Gross margin 2022: € 483,482 First fiscal year in the series	€ 453,821 Gross margin 2023: € 453,821 ▼ 6% vs 2022 (€ 483,482) Unfavourable step	€ 602,949 Gross margin 2024: € 602,949 ▲ 33% vs 2023 (€ 453,821) Favourable step	€ 248,353 Gross margin 2025: € 248,353 ▼ 59% vs 2024 (€ 602,949) Unfavourable step	▼ 59%
Profit after taxes	€ 92,689 Profit after taxes 2022: € 92,689 First fiscal year in the series	€ 50,938 Profit after taxes 2023: € 50,938 ▼ 45% vs 2022 (€ 92,689) Unfavourable step	€ 78,352 Profit after taxes 2024: € 78,352 ▲ 54% vs 2023 (€ 50,938) Favourable step	€ 15,884 Profit after taxes 2025: € 15,884 ▼ 80% vs 2024 (€ 78,352) Unfavourable step	▼ 80%
Equity	€ 1,098,864 Equity 2022: € 1,098,864 First fiscal year in the series	€ 781,803 Equity 2023: € 781,803 ▼ 29% vs 2022 (€ 1,098,864) Unfavourable step	€ 860,154 Equity 2024: € 860,154 ▲ 10% vs 2023 (€ 781,803) Favourable step	€ 876,038 Equity 2025: € 876,038 ▲ 2% vs 2024 (€ 860,154) Favourable step	▲ 2%
Total debts	€ 226,450 Total debts 2022: € 226,450 First fiscal year in the series	€ 296,324 Total debts 2023: € 296,324 ▲ 31% vs 2022 (€ 226,450) Unfavourable step	€ 189,118 Total debts 2024: € 189,118 ▼ 36% vs 2023 (€ 296,324) Favourable step	€ 152,303 Total debts 2025: € 152,303 ▼ 19% vs 2024 (€ 189,118) Favourable step	▼ 19%
Cash	€ 13,408 Cash 2022: € 13,408 First fiscal year in the series	€ 11,810 Cash 2023: € 11,810 ▼ 12% vs 2022 (€ 13,408) Unfavourable step	€ 5,478 Cash 2024: € 5,478 ▼ 54% vs 2023 (€ 11,810) Unfavourable step	€ 5,375 Cash 2025: € 5,375 ▼ 2% vs 2024 (€ 5,478) Unfavourable step	▼ 2%
Land & buildings	€ 534,765 Land & buildings 2022: € 534,765 First fiscal year in the series	€ 498,303 Land & buildings 2023: € 498,303 ▼ 7% vs 2022 (€ 534,765) Unchanged	€ 217,529 Land & buildings 2024: € 217,529 ▼ 56% vs 2023 (€ 498,303) Unchanged	€ 219,725 Land & buildings 2025: € 219,725 ▲ 1% vs 2024 (€ 217,529) Unchanged	▲ 1%
Retained profit	€ 1,036,864 Retained profit 2022: € 1,036,864 First fiscal year in the series	€ 719,803 Retained profit 2023: € 719,803 ▼ 31% vs 2022 (€ 1,036,864) Unfavourable step	€ 798,154 Retained profit 2024: € 798,154 ▲ 11% vs 2023 (€ 719,803) Favourable step	€ 814,038 Retained profit 2025: € 814,038 ▲ 2% vs 2024 (€ 798,154) Favourable step	▲ 2%
Dividend	€ 0 Dividend 2022: € 0 First fiscal year in the series	€ 368,000 Dividend 2023: € 368,000 Unchanged (€ 0) Unchanged	€ 0 Dividend 2024: € 0 ▼ 100% vs 2023 (€ 368,000) Unchanged	€ 0 Dividend 2025: € 0 Unchanged (€ 0) Unchanged
Balance sheet total	€ 1,325,314 Balance sheet total 2022: € 1,325,314 First fiscal year in the series	€ 1,078,127 Balance sheet total 2023: € 1,078,127 ▼ 19% vs 2022 (€ 1,325,314) Unchanged	€ 1,049,272 Balance sheet total 2024: € 1,049,272 ▼ 3% vs 2023 (€ 1,078,127) Unchanged	€ 1,028,341 Balance sheet total 2025: € 1,028,341 ▼ 2% vs 2024 (€ 1,049,272) Unchanged	▼ 2%
Employees (FTE)	5.6 Employees (FTE) 2022: 5.6 First fiscal year in the series	5.9 Employees (FTE) 2023: 5.9 ▲ 0.3 vs 2022 (5.6) Unchanged	4.2 Employees (FTE) 2024: 4.2 ▼ 1.7 vs 2023 (5.9) Unchanged	4.1 Employees (FTE) 2025: 4.1 ▼ 0.1 vs 2024 (4.2) Unchanged	▼ 0.1

Key figures of PHARMA PLUS, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.

What happened to PHARMA PLUS?

What happened at PHARMA PLUS in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

May 12, 2026 New annual accounts for financial year 2025: profit of € 15,884 (▼ 80% vs 2024). Source: NBB ↗
2022 Alexo SRL became a director. NBB
2020 Sodiap SRL became a director. NBB
Feb 2, 1988 New establishment in Boussu. KBO
Dec 21, 1987 Start of the company according to the CBE. KBO

In short

From € 92,689 profit in 2022 to € 15,884 profit in 2025.

Paid € 96,464 in corporate taxes since 2022.

Best year ever: 2022, with € 92,689 profit.

On average € 60,600 of value added per employee in 2025.

Original PDFs at the National Bank ↗

Management

SODIAP 100%

The stake of SODIAP comes from that shareholder’s own annual accounts; small companies do not report their shareholders themselves.

PHARMA PLUS

Behind PHARMA PLUS are Sodiap SRL and Alexo SRL. The shares are held by SODIAP (100%).

Directors

According to the 2025 annual accounts

Sodiap SRL

Managing director · represented by Tom Goderis

Also active at: SDC, HC Pharma, APOTHEEK JENNE, Apotheek de Lisseweg, Apotheek Seurinck, APOTHEEK SCARPHOUT, C.E. FARMA, SANIFAR +24 more

since 2020

Alexo SRL

Chairman of the board · represented by Olivier Delaere

Also active at: SDC, HC Pharma, SODIAP, APOTHEEK JENNE, PANNOC CHEMIE, Apotheek de Lisseweg, Apotheek Seurinck, APOTHEEK SCARPHOUT +34 more

since 2022

Shareholders

SODIAP

100%

Participations

No participations in other companies reported.

Establishments

Establishment units

Physical locations of this company

Registered office

Rue Alfred Dendal(B) 192

7300 Boussu

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number

0432.850.028

VAT number

BE 0432.850.028

Registered office

Rue Alfred Dendal(B) 192, 7300 Boussu

Names & denominations

PHARMA PLUS

Enterprise type

Rechtspersoon

Legal form

Private limited company

Legal situation

Normale toestand

Start date

21 December 1987

Peppol

Active · Active since 6 Jun 2025

Activities · NACE

Detailhandel in farmaceutische producten

Apothekers

View on CBE Public ↗ Annual accounts (NBB) ↗

PHARMA PLUS

Warning lights

Financials

What happened to PHARMA PLUS?

Management

Directors

Shareholders

Participations

Establishments

Establishment units

Details

Frequently asked questions